Simple test may predict danger in new cancer therapies for seniors

NCT ID NCT07309497

First seen Jan 05, 2026 · Last updated May 06, 2026 · Updated 16 times

Summary

This study looks at whether a quick, practical health assessment can help predict serious side effects in people aged 65 and older who are about to receive CAR-T cell or bispecific antibody therapy for certain blood cancers. Researchers will evaluate patients' mobility, memory, self-care, and nutrition before treatment and track their outcomes. The goal is to see if this assessment can better identify who is at higher risk, leading to more personalized care and improved quality of life.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BISPECIFIC ANTIBODY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Inselspital Bern

    RECRUITING

    Bern, Switzerland

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Universitätsspital Zürich

    RECRUITING

    Zurich, 8091, Switzerland

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.